Is Haleon stock a buy right now?
As of early May 2025, Haleon shares trade at approximately 403.70 GBX on the London Stock Exchange, with average daily turnover reaching 25.22 million shares. Recent weeks have seen Haleon deliver solid Q1 results, demonstrating 3.5% organic revenue growth led by expanding demand in oral health and emerging markets such as India and China. The company’s share price reflects resilience, outperforming broader sector indices and trading above its 50- and 200-day moving averages—a technical signal many consider constructive. Market sentiment remains subtly optimistic, with Haleon's ongoing innovation (notably the new Sensodyne Clinical platform), ambitious share buybacks, and its acquisition of the remainder of its China OTC joint venture emphasizing management’s commitment to growth and shareholder value. While global macroeconomic conditions remain challenging, Haleon’s defensive qualities and low share price volatility (beta: 0.21) continue to attract selective interest. In the context of the consumer health sector—a space prized for stability and everyday relevance—analysts from over 32 respected national and international banks have now set a consensus target price at 525 GBX, highlighting faith in a business model well placed to deliver steady returns.
- Diversified global portfolio minimizing reliance on any single product or region.
- Strong organic growth in key categories like oral health and pain relief.
- Robust expansion in emerging markets, particularly China and India.
- Active share repurchase programme supporting shareholder value.
- Innovation pipeline driving ongoing product launches and market share gains.
- Exposure to currency headwinds and global macroeconomic uncertainty.
- Competitive pressures in North American VMS could modestly impact short-term growth rates.
- What is Haleon?
- How much is Haleon stock?
- Our full analysis on Haleon </b>stock
- How to buy Haleon stock in United Kingdom?
- Our 7 tips for buying Haleon stock
- The latest news about Haleon
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of Haleon for over three years. Every month, hundreds of thousands of users in the United Kingdom rely on us to interpret market trends and highlight the best investment opportunities. Our reports are produced for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, paid by Haleon.
What is Haleon?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | UK-based, offering strong links to European and global consumer health markets. |
| 💼 Market | London Stock Exchange (LSE: HLN) | Primary listing on LSE, ensuring good liquidity and regulatory oversight. |
| 🏛️ ISIN code | GB00BMX86B70 | International identifier, simplifying trading and investment for global investors. |
| 👤 CEO | Brian McNamara | Experienced leader with a track record in global consumer health business. |
| 🏢 Market cap | £35.05 billion | Large-cap status indicates maturity and stability in the sector. |
| 📈 Revenue | £11.30 billion (TTM, estimate) | Strong revenue base, slightly impacted by currency headwinds and divestments. |
| 💹 EBITDA | ~£2.5 billion (TTM, estimate) | Healthy EBITDA supports reinvestment in innovation and shareholder returns. |
| 📊 P/E Ratio (Price/Earnings) | 24.75 (TTM), 20.25 (Forward) | Mid-20s P/E reflects growth potential, but not considered inexpensive relative to peers. |
How much is Haleon stock?
The price of Haleon stock is rising this week. As of now, Haleon shares are trading at 403.70 GBX, reflecting an increase of 15.00 GBX (+3.86%) over the past 24 hours and a weekly gain as the stock continues its upward momentum. The company’s market capitalisation stands at £35.05 billion, with a robust average trading volume of 25.22 million shares over the last three months. Haleon holds a P/E ratio of 24.75, offering a dividend yield of 1.75%, and a stock beta of 0.21, indicating lower volatility compared to the broader UK market. This strong performance suggests Haleon remains a stable and attractive option for investors seeking steady exposure to the consumer health sector.
Compare the best brokers in the UK!Compare brokersOur full analysis on Haleon stock
Following an in-depth review of Haleon PLC’s latest financial statements and a comprehensive assessment of its stock performance over the past three years, our analytical approach has leveraged a fusion of financial metrics, technical indicators, and peer comparisons—augmented by advanced proprietary algorithms—to distil actionable insight. As the global leader in consumer health, Haleon has navigated recent market volatility with a blend of resilience and innovation. So, why might Haleon stock once again become a strategic entry point into the consumer health sector in 2025?
Recent Performance and Market Context
Haleon’s performance year-to-date underscores a notable recovery and an emerging upward momentum within the consumer health sector. As of 2 May 2025, shares are quoted at 403.70 GBX, exhibiting a robust daily climb of +3.86%, which places them close to their 52-week high of 417.70 GBX. This positive price action is driven by a confluence of encouraging factors:
- Q1 2025 Organic Revenue Growth: The company posted +3.5% organic revenue growth, reflecting sound execution and resilience against macroeconomic headwinds. Momentum is particularly compelling in EMEA & Latin America (+5.0%) and Asia-Pacific (+4.2%), while North America continues to grow at a more moderate pace.
- Strong Category Fundamentals: Oral health (+6.6%) and Pain relief (+2.6%) categories have continued to outperform, powered by innovation in flagship brands such as Sensodyne and Advil.
- Sector Tailwinds: The broader healthcare industry continues to benefit from sustained demand for self-care, wellness, and over-the-counter solutions, outpacing many traditional pharma segments.
- Favourable Market Sentiment: A low beta of 0.21 reflects relative insulation from equity market turbulence, increasing Haleon’s appeal for investors seeking defensive growth.
Taken together, these factors signal a supportive backdrop, amplifying Haleon’s appeal as its long-term growth narrative further takes shape.
Technical Analysis
From a technical perspective, Haleon shares have transitioned into a distinctly favourable structure:
- Moving Averages: The current share price comfortably sits above the 50-day moving average (approx. 387–390 GBX) and the 200-day moving average (upper 370s GBX). This alignment is widely viewed by market participants as a bullish confirmation of current trend strength.
- Momentum Signals: The 14-day Relative Strength Index (RSI) hovers around 50–51, indicating the stock is neither overbought nor oversold—thus offering an ideal entry point before potential breakout movements. The MACD reading (+1.2) further reinforces the upward drift, with momentum building but not yet exhausted.
- Key Technical Levels:
- Strong support is evident between 386–390 GBX (50-day MA) and 375–380 GBX (200-day MA).
- Immediate resistance is established at 417.70 GBX (52-week high), suggesting room for potential further upside should this level be breached.
- Short- and Medium-Term Structure: The combination of healthy volume, positive momentum, and well-supported price action underlines the prospect for near-term continuation of the current uptrend.
For investors interpreting Haleon’s chart, these technical factors indicate the stock may be entering a new bullish phase, with limited downside risk while support levels hold firm.
Fundamental Analysis
Haleon’s fundamentals clearly justify renewed interest, particularly as its business model, capital allocation, and innovation strategy converge in a period of global consumer health expansion:
- Consistent Revenue Growth: Despite reported revenue contraction due to divestments and FX, underlying organic growth remains robust (+3.5% in Q1 2025). Management is guiding for +4–6% organic revenue growth for FY2025, with a second-half skew—providing clear visibility and confidence.
- Visible Profitability and Capital Returns: Operating profit growth is expected to outpace revenue, further supported by an aggressive share buyback plan (£500 million allocated in 2025). These actions reinforce Haleon's disciplined capital stewardship.
- Attractive Valuation Metrics: At a forward P/E of ~20.25x and a trailing P/E of 24.75x, the stock trades at a premium to the broader market but remains justified by superior growth credentials and a fortified balance sheet. The current dividend yield of 1.75% (annual 6.60 GBX) offers additional income appeal.
- Structural Strengths: Haleon’s global leadership in flagship brands (Sensodyne, Voltaren, Advil) and strong market shares in both developed and fast-growing emerging economies (notably India and China) create a durable competitive moat. The acquisition of the remaining 12% in its China OTC joint venture signals both conviction and optimism about future regional growth.
- Innovation and Market Share: Successful product launches in key segments and continued investment in R&D underpin the company’s ability to sustain outperformance over the medium term.
Collectively, these pillars establish Haleon as a fundamentally resilient and strategically agile operator—attributes highly prized in the current macroeconomic climate.
Volume and Liquidity
Haleon’s robust liquidity profile further bolsters market confidence:
- Sustained Trading Volume: With an average daily turnover of over 25 million shares, Haleon’s high liquidity facilitates efficient trade execution and reflects strong institutional interest.
- Dynamic Free Float: The ongoing share buybacks—especially the £330 million open-market programme throughout 2025—not only signal management’s confidence in intrinsic value, but also enhance per-share metrics, benefitting ongoing valuation dynamics.
- Market Depth: The combination of major FTSE 100 inclusion and broad analyst coverage ensures the stock remains in focus for a wide spectrum of market participants, which historically helps support tighter spreads and price stability.
This depth and liquidity landscape positions Haleon as a core holding candidate for both selective capital and systematic allocation strategies.
Catalysts and Positive Outlook
Multiple bullish catalysts on the horizon strengthen the case for Haleon’s continued outperformance:
- Product Innovation Pipeline: Recent launches such as the Sensodyne Clinical platform, Otrivin Nasal Mist, and expanded oral care lines are driving incremental market share and category expansion.
- M&A and Geographic Scaling: The full ownership of the key Chinese OTC operation opens up significant long-term growth prospects in one of the world’s highest-potential markets. Emerging market momentum (+6.5% organic in Q1) is expected to accelerate in H2 2025, in line with management’s guidance.
- Active Capital Returns: The announcement and execution of the £500 million buyback deliver direct shareholder value and reinforce confidence in future earnings power.
- Sector Trends and ESG: The consumer health sector enjoys powerful secular tailwinds: ageing demographics, rising health awareness, and a structural shift towards self-care. Haleon’s focus on sustainability within product innovation and supply chain management aligns with increasing ESG demands from institutional investors.
- Defensive Growth Features: In a macro climate marked by sporadic volatility, Haleon’s lower beta and countercyclical demand profile offer investors a rare blend of downside protection and growth exposure.
These converging positives heighten the probability that Haleon will remain a relative outperformer within the sector, particularly as catalysts begin to materialise in the coming quarters.
Investment Strategies
Haleon’s technical structure and business momentum favour a multi-horizon investment approach:
- Short-Term:
- For technically oriented investors, current levels just above the 50- and 200-day moving averages offer an advantageous entry point. With RSI in a neutral zone and the MACD trending higher, any retest of support (e.g., 390 GBX) may present a low-risk setup. A breakout above the 417.70 GBX resistance could unlock swift tactical upside.
- Medium-Term:
- The forecasted acceleration in organic revenue and profit in H2 2025, combined with active buyback execution, sets up a constructive environment for price appreciation across the coming quarters. The second-half weighting provides a clear time window for potential re-rating.
- Long-Term:
- As demographic shifts, healthcare innovation, and emerging market expansion define the next cycle, Haleon's diversified global platform and strong balance sheet warrant inclusion in a growth and income portfolio. The brand’s compounding power—propelled by persistent R&D, category leadership, and disciplined financial management—supports sustained value creation well beyond 2025.
Hence, current price levels and fundamental trajectory seem to represent an excellent opportunity for building exposure across varying risk and strategy profiles.
Is it the Right Time to Buy Haleon?
Haleon’s combination of strong organic growth, disciplined capital returns, innovation in core categories, and aggressive expansion into high-growth emerging markets sharply distinguishes it from peers. Trading above key moving averages with active upward momentum, and underpinned by a visible acceleration in financial performance and unique catalysts into H2 2025, the stock presents a compelling case for renewed investor interest. While macroeconomic uncertainty persists, Haleon’s defensive qualities and robust structural dynamics appear ideally suited for those seeking exposure to the consumer health sector.
With a healthy balance of growth, resilience, and liquidity, Haleon seems to be entering a phase where upside potential materially outweighs near-term risks. For investors in search of a well-positioned, market-leading player poised to capture secular health and wellness trends, Haleon’s present valuation and outlook may well deserve a central place on the shortlist of strategic consumer health investments for 2025. This moment could offer a timely and rewarding alignment between company execution, sector momentum, and investor opportunity.
How to buy Haleon stock in United Kingdom?
Buying shares in Haleon PLC online is both straightforward and secure when using a regulated UK broker. Investors have two main options: buying shares outright (known as spot or cash buying), or trading with contracts for difference (CFDs), which allow speculation on price movements with leverage. Both choices let you gain exposure to Haleon's performance, but involve different approaches to fees, risk, and ownership. For those keen to get started, it’s wise to examine brokers’ features and charges—see our comparison table further down the page for more details.
Spot buying
When you buy Haleon shares for cash, you become a direct shareholder—meaning you actually own the number of shares purchased and may be eligible for dividends. UK brokers typically charge a fixed commission per transaction, often between £1 and £10 per order. Some also offer share-dealing accounts with monthly plans for frequent traders or discounted rates.
Example
Suppose the Haleon share price is 403.70 GBX (that’s £4.037). With a £1,000 investment, you could buy approximately 247 Haleon shares (1,000 ÷ 4.037), assuming a typical brokerage fee of £5.
✔️ Gain scenario:
If the share price rises by 10%, your shares are now worth £1,100.
Result: That’s a £100 gross gain, or +10% on your investment (before any additional costs or taxes).
Trading via CFD
CFD (Contract for Difference) trading lets you speculate on Haleon's share price without owning the underlying shares. You can trade on price movements with leverage: this means you control a larger exposure with a smaller deposit (margin). CFD brokers make money via the bid/ask spread, and may charge overnight financing fees if you hold positions beyond the trading day.
Example
You want to gain exposure to Haleon with a £1,000 stake and use 5x leverage. Your market exposure becomes £5,000.
✔️ Gain scenario:
If Haleon's stock rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a £400 gain on your initial £1,000, excluding spread and overnight fees.
Final advice
Before investing, always compare brokers’ commissions, spreads, and account terms; the best choice depends on your investment style, desired level of risk, and whether you want to own the shares or simply trade their price movements. Consult our broker comparison below to find an option that best matches your needs and objectives. Ultimately, the decision between buying or trading Haleon shares comes down to your goals, risk appetite, and investment horizon.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying Haleon stock
| Step | Specific tip for Haleon |
|---|---|
| Analyze the market | Review trends in the consumer health sector and Haleon’s recent organic growth, especially in emerging markets like India and China, to gauge demand strength. |
| Choose the right trading platform | Opt for a UK-regulated broker that provides easy access to the London Stock Exchange and offers competitive commissions on LSE-listed shares like Haleon. |
| Define your investment budget | Allocate an amount that fits your risk profile, bearing in mind Haleon’s low beta for stability, but diversify to manage sector-specific risks effectively. |
| Choose a strategy (short or long term) | Consider a long-term approach, as Haleon’s strategic share buybacks and global expansion are expected to support steady growth over the coming years. |
| Monitor news and financial results | Keep a close eye on Haleon’s quarterly earnings, product launches, and announcements regarding innovation and geographic expansion for timely investment decisions. |
| Use risk management tools | Set up stop-loss limits or trailing stops to protect your investment in case of market downturns, even though Haleon is less volatile than the broader market. |
| Sell at the right time | Look for opportunities to take profits if Haleon approaches resistance or nears its 52-week high, or ahead of key events that could impact the share price. |
The latest news about Haleon
Haleon shares rise nearly 4% as Q1 2025 organic growth and innovation impress the market. Following the release of its Q1 2025 results on 2 May, Haleon’s stock rallied by 3.86% on the London Stock Exchange, closing at 403.70 GBX, decisively above its 50- and 200-day moving averages, which underlines positive market sentiment. Investors reacted favourably to the company’s 3.5% organic revenue growth, with UK and Europe (the EMEA segment) performing strongly at +5.0%. This momentum reflects robust consumer demand for leading brands such as Sensodyne, parodontax, and Voltaren, all widely distributed in the UK, signalling healthy underlying business activity in its home market.
Haleon initiates substantial share buyback to return value to shareholders, strengthening confidence for UK investors. In March 2025, the company launched the final tranche of its £500 million share buyback programme, with £170 million in shares already repurchased and up to £330 million more allocated for on-market repurchases this year. This ongoing capital return strategy, along with a confirmed annual dividend of 6.60 GBX due on 5 June 2025, underscores management’s active commitment to enhancing shareholder value; a strong reassurance for institutional and retail investors based in the United Kingdom.
Strong oral health category performance, led by Sensodyne and parodontax, drives growth in the UK market. Haleon posted a 6.6% organic growth in its oral health category in Q1 2025, thanks to successful launches under the Sensodyne Clinical platform and double-digit growth in parodontax—all popular products in British households and pharmacies. Such category performance not only consolidates Haleon’s leadership in UK oral health but also positions the company at the forefront of consumer preference, even amidst competitive and promotional pressures prevalent in the region.
Full-year guidance reaffirmed, highlighting resilience and strategic clarity despite regional macroeconomic challenges. Despite management’s acknowledgment of challenging and uncertain macroeconomic conditions, the company reaffirmed its full-year organic revenue growth target of 4–6% and expects operating profit growth to outpace revenue gains, particularly in the second half of 2025. This public reaffirmation reflects operational resilience and confidence in its UK-driven business model, which is of specific relevance to analysts tracking stable, mature market stocks.
Acquisition of full ownership in China OTC business expands global footprint and supports Haleon’s UK-centred international profile. In a strategic transaction announced this week, Haleon agreed to acquire the remaining 12% stake in its China OTC joint venture for approximately £0.2 billion, giving it total control over its operations in a major growth market. This move not only diversifies profit streams beyond the UK and Europe but also demonstrates the company’s ability to leverage its strong London headquarters as a base for disciplined international expansion, ultimately enhancing long-term growth prospects valued by UK-based investors and analysts.
FAQ
What is the latest dividend for Haleon stock?
Haleon currently pays a dividend of 6.60 GBX per share annually. The next payment is scheduled for 5 June 2025, with the ex-dividend date set for 24 April 2025. This dividend corresponds to a yield of 1.75%. Haleon has a consistent distribution policy, reflecting financial stability and commitment to returning value to shareholders.
What is the forecast for Haleon stock in 2025, 2026, and 2027?
Based on the current price of 403.70 GBX, the projections are 525 GBX for the end of 2025, 605 GBX for the end of 2026, and 807 GBX for the end of 2027. These forecasts suggest a credible upward trend supported by solid fundamentals, continuing product innovation, and successful expansion into fast-growing markets like China and India.
Should I sell my Haleon shares?
Holding Haleon shares could be a prudent choice given the company’s stable valuation, robust brand portfolio, and proven ability to grow organically, even in a challenging macroeconomic environment. The stock’s low volatility and presence in defensive consumer health categories further enhance its mid- to long-term appeal. Retaining shares may be suitable for investors seeking resilience and gradual growth from a leading sector player.
Are Haleon shares eligible for a Stocks and Shares ISA in the UK, and how are dividends taxed?
Yes, Haleon shares listed on the LSE are eligible to be held within a UK Stocks and Shares ISA. Dividends earned within an ISA are not subject to UK income tax, and any capital gains are also tax-free. For shares held outside an ISA, UK dividend tax rules apply above the annual dividend allowance, making ISA wrappers particularly beneficial for investors.
What is the latest dividend for Haleon stock?
Haleon currently pays a dividend of 6.60 GBX per share annually. The next payment is scheduled for 5 June 2025, with the ex-dividend date set for 24 April 2025. This dividend corresponds to a yield of 1.75%. Haleon has a consistent distribution policy, reflecting financial stability and commitment to returning value to shareholders.
What is the forecast for Haleon stock in 2025, 2026, and 2027?
Based on the current price of 403.70 GBX, the projections are 525 GBX for the end of 2025, 605 GBX for the end of 2026, and 807 GBX for the end of 2027. These forecasts suggest a credible upward trend supported by solid fundamentals, continuing product innovation, and successful expansion into fast-growing markets like China and India.
Should I sell my Haleon shares?
Holding Haleon shares could be a prudent choice given the company’s stable valuation, robust brand portfolio, and proven ability to grow organically, even in a challenging macroeconomic environment. The stock’s low volatility and presence in defensive consumer health categories further enhance its mid- to long-term appeal. Retaining shares may be suitable for investors seeking resilience and gradual growth from a leading sector player.
Are Haleon shares eligible for a Stocks and Shares ISA in the UK, and how are dividends taxed?
Yes, Haleon shares listed on the LSE are eligible to be held within a UK Stocks and Shares ISA. Dividends earned within an ISA are not subject to UK income tax, and any capital gains are also tax-free. For shares held outside an ISA, UK dividend tax rules apply above the annual dividend allowance, making ISA wrappers particularly beneficial for investors.
